Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ONXX
- CUSIP: 68339910
- Web: N/A
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 226.73
- P/E Growth: N/A
Frequently Asked Questions for Onyx Pharmaceuticals (NASDAQ:ONXX)
What is Onyx Pharmaceuticals' stock symbol?
Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."
Who are some of Onyx Pharmaceuticals' key competitors?
Some companies that are related to Onyx Pharmaceuticals include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Anavex Life Sciences Corp. (AVXL), Mirati Therapeutics (MRTX), XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Trillium Therapeutics (TRIL), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY) and Cubist Pharmaceuticals (CBST).
How do I buy Onyx Pharmaceuticals stock?
Shares of Onyx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onyx Pharmaceuticals' stock price today?
MarketBeat Community Rating for Onyx Pharmaceuticals (NASDAQ ONXX)MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Onyx Pharmaceuticals stock can currently be purchased for approximately $124.70.
Consensus Ratings for Onyx Pharmaceuticals (NASDAQ:ONXX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Onyx Pharmaceuticals (NASDAQ:ONXX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Onyx Pharmaceuticals (NASDAQ:ONXX)Earnings History by Quarter for Onyx Pharmaceuticals (NASDAQ ONXX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2013||Q2 2013||($0.42)||($0.40)||$151.73 million||$153.00 million||View||N/A|
|5/7/2013||Q1 2013||($0.47)||($0.19)||$134.36 million||$145.50 million||View||N/A|
|2/21/2013||Q4 2012||($0.76)||($0.36)||$113.17 million||$127.90 million||View||N/A|
|11/1/2012||Q312||($0.95)||($0.79)||$80.02 million||$89.51 million||View||N/A|
Earnings Estimates for Onyx Pharmaceuticals (NASDAQ:ONXX)
Current Year EPS Consensus Estimate: $-1.53 EPS
Next Year EPS Consensus Estimate: $0.55 EPS
Dividend History for Onyx Pharmaceuticals (NASDAQ:ONXX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Onyx Pharmaceuticals (NASDAQ:ONXX)Insider Trades by Quarter for Onyx Pharmaceuticals (NASDAQ:ONXX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/12/2013||Helen Torley||EVP||Sell||9,311||$126.89||$1,181,472.79|| |
|8/8/2013||Matthew Fust||CFO||Sell||2,492||$128.21||$319,499.32|| |
|8/7/2013||Suzanne Shema||EVP||Sell||4,052||$131.86||$534,296.72|| |
|8/6/2013||Kaye Foster-Cheek||SVP||Sell||8,878||$132.81||$1,179,087.18|| |
|7/30/2013||Corinne H Nevinny||Director||Sell||1,500||$131.26||$196,890.00|| |
|7/26/2013||Lopez Antonio J Grillo||Director||Sell||2,000||$130.50||$261,000.00|| |
|7/26/2013||Matthew K Fust||CFO||Sell||6,043||$130.50||$788,611.50|| |
|7/8/2013||Suzanne M Shema||EVP||Sell||4,052||$135.76||$550,099.52|| |
|7/2/2013||Matthew K Fust||CFO||Sell||1,551||$132.80||$205,972.80|| |
|7/1/2013||Juergen Lasowski||EVP||Sell||25,375||$132.63||$3,365,486.25|| |
|7/1/2013||Julianna R Wood||VP||Sell||2,304||$132.63||$305,579.52|| |
|7/1/2013||Paul Goddard||Director||Sell||6,000||$132.21||$793,260.00|| |
|6/19/2013||Corinne H Nevinny||Director||Sell||1,000||$88.25||$88,250.00|| |
|6/10/2013||Julianna R Wood||VP||Sell||2,306||$92.30||$212,843.80|| |
|6/7/2013||Suzanne M Shema||EVP||Sell||4,052||$91.23||$369,663.96|| |
|6/5/2013||N Anthony Coles||CEO||Sell||6,562||$90.00||$590,580.00|| |
|5/14/2013||Juergen Lasowski||EVP||Sell||4,182||$96.60||$403,981.20|| |
|5/13/2013||Helen Torley||EVP||Sell||8,250||$98.13||$809,572.50|| |
|5/13/2013||Matthew K Fust||CFO||Sell||10,269||$98.22||$1,008,621.18|| |
|4/11/2013||Lopez Antonio J Grillo||Director||Sell||43,164||$96.73||$4,175,253.72|| |
|4/10/2013||Julianna R Wood||VP||Sell||9,948||$95.00||$945,060.00|| |
|4/10/2013||Paul Goddard||Director||Sell||2,000||$95.00||$190,000.00|| |
|3/11/2013||Julianna R Wood||VP||Sell||3,331||$85.65||$285,300.15|| |
|3/11/2013||Magnus Lundberg||Director||Sell||5,000||$88.00||$440,000.00|| |
|10/5/2012||Juergen Lasowski||EVP||Sell||5,902||$90.00||$531,180.00|| |
|10/4/2012||Helen Torley||EVP||Sell||2,314||$86.51||$200,184.14|| |
|10/2/2012||Kaye I Foster-Cheek||SVP||Sell||2,015||$85.08||$171,436.20|| |
Headline Trends for Onyx Pharmaceuticals (NASDAQ:ONXX)
Latest Headlines for Onyx Pharmaceuticals (NASDAQ:ONXX)
Onyx Pharmaceuticals (ONXX) Chart for Thursday, July, 27, 2017